Physicians' Academy for Cardiovascular Education

PCSK9i & LDL-c: Guidelines, Practice & Innovation: Review of facts and opportunities

Meeting report with presentation slides, video and online CME of a PACE-CME symposium held during ESC 2020, The Digital Experience.

E-learning PCSK9i & LDL-c: Guidelines, Practice and Innovation

EBAC-accredited E-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

In this video series, three experts present the most important changes in the ESC/EAS dyslipidemia guidelines, lessons learned after 5 years of use with PCSK9 inhibitors, and implemental gaps in the use of lipid-lowering therapies.

Introduction: PCSK9i & LDL-c - Guidelines, Practice & Innovation

10' education - Nov. 9, 2020 - Prof. John Kastelein, MD
Prof. Kastelein gives an introduction to the symposium about LDL-c lowering therapies via PCSK9 inhibition, that was held during the virtual ESC 2020 congress.

Prof. Kastelein gives an introduction to the symposium about LDL-c lowering therapies with a specifiek focus on PSCK9 inhibition that was held during the virtual ESC 2020 congress.

Time to reduce implementation gaps of lipid-lowering therapy

10' education - Nov. 6, 2020 - Prof. Kausik Ray, MD - Online CME
Attainment of risk-based LDL-c goals in the ESC/EAS guidelines is low due to implementation gaps, but even with optimal statin use, combination therapy with PCSK9i is often needed to achieve 2019 LDL-c goals.

Attainment of risk-based LDL-c goals in the ESC/EAS guidelines is low due to implementation gaps, but even with optimal statin use, combination therapy with PCSK9i is often needed to achieve 2019 LDL-c goals.

Five years of PCSK9i - Lessons from practice: Which patients benefit most?

10' education - Sep. 30, 2020 - Prof. Erik Stroes, MD - Online CME
Prof. Stroes discusses the efficacy of PCSK9 and which patients benefit most from LDL-c lowering (combination) therapies.

Prof. Stroes discusses the efficacy of PCSK9 inhibitors and which patients benefit most from LDL-c lowering (combination) therapies.

One year after the new ESC/EAS dyslipidemia guidelines

10' education - Sep. 17, 2020 - Prof. François Mach - Online CME
Prof. Mach discusses how CV risk and circulating LDL-c can be reduced by lipid-lowering agents and current guideline recommendations to manage CV risk.

Prof. Mach discusses the concepts for lipid lowering treatment as defined in the 2019 ESC/EAS dyslipidemia guidelines.

Discussion: PCSK9i & LDL-c: Guidelines, Practice & Innovation

Sep. 9, 2020

Expert discussion on PCSK9i & LDL-c: Guidelines, Practice & Innovation.

PCSK9i & LDL-c: Guidelines, Practice & Innovation: Review of facts and opportunities